Ruben Mesa/LinkedIn
Aug 31, 2026, 14:28
Ruben Mesa: FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia
Ruben Mesa, President of Cancer National Service Line at Advocate Health, shared a post on LinkedIn:
“Honored to have been involved with (as PI of the Global Surpass ET trial) the now FDA approval of ROPEG INF a2b for patients with Essential Thrombocythemia.
This is the first approval in over 30 years for patients with this myeloid neoplasm MPN and helps decrease disease associated risks, symptoms, and modifies the underlying clone.”
Stay updated with Hemostasis Today.
-
Aug 31, 2026, 15:21Ney Carter Borges: Anticoagulation Versus Antiplatelet Therapy After TAVI ESC 26
-
Aug 31, 2026, 15:13Nahid A. Qushmaq: MicroRNAs as Prognostic Biomarkers in Septic Patients
-
Aug 31, 2026, 14:32Mahir Khalil Ibrahim Jallo: Hot Topic From The ESC 2026 Munich
-
Aug 31, 2026, 14:28Francisco Chacón-Lozsán: Should We Anticoagulate AF Patients With Only One Non-Sex Stroke Risk Factor?
-
Aug 31, 2026, 14:24Akl Fahed: Do Lifelong Differences in LDL Cholesterol Influence the Risk of Venous Thromboembolism?
-
Aug 31, 2026, 14:23Accelerating CAR-T Access Through Policy and System Reform – American Society of Hematology
-
Aug 31, 2026, 14:21Shirya Rashid: Does Bempedoic Acid Influence Venous Thromboembolism Risk?
-
Aug 31, 2026, 14:14Jason Andrade: SINGLE-AF Trial Validates Early Anticoagulation in AF
-
Aug 31, 2026, 14:12Leonardo Roever: Diagnosis and Management of Natural Anticoagulant Deficiencies